3D Time-of-Flight Magnetic Resonance Angiography in Hemodialysis Patients With Arteriovenous Fistula
To Assess the Value of 3D Time-of-Flight Magnetic Resonance Angiography in Hemodialysis Patients With Occlusive Disease in Arteriovenous Fistula
1 other identifier
interventional
68
1 country
1
Brief Summary
This study is aimed to assess the value of three-dimensional time-of-flight magnetic resonance angiography (3D-TOF-MRA) in hemodialysis patients with occlusive disease in arteriovenous fistula (AVF). All participants will receive 3D-TOF-MRA and ultrasound to detect the stenosis degree of AVF.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2018
CompletedFirst Submitted
Initial submission to the registry
March 12, 2020
CompletedFirst Posted
Study publicly available on registry
March 18, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2021
CompletedJanuary 11, 2022
January 1, 2022
1.8 years
March 12, 2020
January 5, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
degree of stenosis
visual grading system: 0 = completely smooth vessel wall; 1. = \<50% stenosis; 2. = 50%-75% stenosis; 3. = 75%-99% stenosis; 4. = occlusion.
immediately after examination finished
stenosis location
1. = arterial vessel of AVF 2. = orifice of AVF 3. = venous vessel of AVF
immediately after examination finished
Study Arms (1)
intervention
EXPERIMENTALAll participants received 3D-TOF-MRA and ultrasound examination, and DSA is used as golden reference
Interventions
The Principle of 3D-TOF-MRA is based on the "flow effect" of MR. In the GE sequence of MRA imaging, the effect of RF pulses makes the protons in the stationary tissue in the active layer in a saturated state, and the longitudinal magnetization disappears. When the inflow blood appears, its protons are in an unsaturated state and have a high degree of longitudinal magnetization. In this way, a clear difference is formed between saturated tissue and unsaturated flowing blood to display blood vessels. 3D-TOF-MRA is a non-invasive and safe method for diagnosing vascular diseases.
Eligibility Criteria
You may qualify if:
- hemodialysis patients suspected of occlusive disease in arteriovenous fistula (AVF);
- persistent edema of the limb with the fistula;
- decreased pulse or fremitus in anastomotic astium
- increase in venous pressure; blood flow at the access of less than 200 mL/min;
You may not qualify if:
- previous endovascular recanalization with stent or graft placement;
- contraindications to magnetic resonance imaging (MRI) examination;
- platelet(PLT)\<60\*10\^9/L or international normalized ratio (INR)\>1.5; 4. important organ function failure or other serious illness; 5. Allergic to antiplatelet drug, anticoagulant drug, anaesthetic drug and contrast material.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanghai 6th People's Hospital
Shanghai, 200023, China
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yue-Qi Zhu, Dr
Shanghai 6th People's Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
March 12, 2020
First Posted
March 18, 2020
Study Start
December 1, 2018
Primary Completion
October 1, 2020
Study Completion
March 31, 2021
Last Updated
January 11, 2022
Record last verified: 2022-01
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be made avaliable.